Can Rozebalamin (methylcobalamin) cure ALS?

Rozebalamin (methylcobalamin) currently does not cure ALS (ALS), but it can slow down the progression of the disease to a certain extent and help delay the worsening of functional impairment. ALS is a degenerative disease of the nervous system for which there is currently no cure. RozebalaminAs a neuroprotective drug, it helps reduce the negative effects of neurodegenerative diseases by increasing the resistance of nerve cells to neurodegeneration. Although it cannot completely cure ALS, it can improve the patient's quality of life and extend the patient's survival time to a certain extent.

Research suggests that methylcobalamin may slow the progression of ALS by promoting axonal regeneration and improving neuroprotection. Nonclinical studies suggest that methylcobalamin may play an important role in maintaining the function and structure of nerve cells, but these findings do not fully support its ability to cure ALS. In other words, Rozebalamin is used more as an auxiliary treatment to control symptoms and delay the progression of the disease rather than to cure the disease.

In clinical use, patients' responses toRozebalamin vary depending on individual differences. Some patients may feel that their symptoms are relieved or alleviated, and then maintain relatively stable life functions, but some patients do not see obvious effects during use. Therefore, while Rozebalaminprovides a treatment option for ALS patients, there is no guarantee that all patients will achieve cure or significant clinical improvement.

In summary,Rozebalaminis not a cure for ALS, but rather a drug that helps slow the progression of the disease through neuroprotection. For ALS patients, the role of drugs is to delay the progression of the disease and improve symptoms, rather than to cure them completely. Therefore, the treatment of ALS still requires a combination of multiple aspects of management, including drugs, physical therapy, supportive care, etc.

xa0

References:

[1]https://pins.japic.or.jp/pdf/newPINS/00071540.pdf

[2]https://www.eisai.com/news/2024/news202487.html